WaveMan
WaveMan · Company
HHS · Harte Hanks Inc
> Search tickers & screens ⌘K
LIVE
← All companies

HHS Harte Hanks (HHS) Insider Trading, Ownership & Congress Trades

Services · Services-direct mail advertising services · CIK 0000045919
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
5
13F, latest reported quarter

Harte Hanks insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for HARTE HANKS INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Radoff Bradley Louis
Director
BUY
2024-12-06 SECtraded 2024-12-05
99
$582
-32.5%
Context
  • 32 earlier Form 4 trades (code P or S) here by this insider (27 buys, 5 sales), the last on Dec 4, 2024.
  • -3.8% median (-1.6% mean) 90-day return after 6 previous buys.
  • The trade is 0.0% of the 389,871 shares held after it.
  • 1 other insider bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Radoff Bradley Louis bought about $582 of HHS on Dec 5, 2024; 1 other insider bought within 30 days and 5 funds added in the latest 13F quarter.
Radoff Bradley Louis
Director
BUY
2024-12-06 SECtraded 2024-12-05
117
$689
-32.5%
Context
  • 32 earlier Form 4 trades (code P or S) here by this insider (27 buys, 5 sales), the last on Dec 4, 2024.
  • -3.8% median (-1.6% mean) 90-day return after 6 previous buys.
  • The trade is 0.0% of the 389,988 shares held after it.
  • 1 other insider bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Radoff Bradley Louis bought about $689 of HHS on Dec 5, 2024; 1 other insider bought within 30 days and 5 funds added in the latest 13F quarter.
Radoff Bradley Louis
Director
BUY
2024-12-06 SECtraded 2024-12-05
327
$1.9K
-32.5%
Context
  • 32 earlier Form 4 trades (code P or S) here by this insider (27 buys, 5 sales), the last on Dec 4, 2024.
  • -3.8% median (-1.6% mean) 90-day return after 6 previous buys.
  • The trade is 0.1% of the 390,315 shares held after it.
  • 1 other insider bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Radoff Bradley Louis bought about $1.9K of HHS on Dec 5, 2024; 1 other insider bought within 30 days and 5 funds added in the latest 13F quarter.
Radoff Bradley Louis
Director
BUY
2024-12-06 SECtraded 2024-12-05
1,084
$6.4K
-32.5%
Context
  • 32 earlier Form 4 trades (code P or S) here by this insider (27 buys, 5 sales), the last on Dec 4, 2024.
  • -3.8% median (-1.6% mean) 90-day return after 6 previous buys.
  • The trade is 0.3% of the 391,399 shares held after it.
  • 1 other insider bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Radoff Bradley Louis bought about $6.4K of HHS on Dec 5, 2024; 1 other insider bought within 30 days and 5 funds added in the latest 13F quarter.
Radoff Bradley Louis
Director
BUY
2024-12-06 SECtraded 2024-12-05
200
$1.1K
-32.5%
Context
  • 32 earlier Form 4 trades (code P or S) here by this insider (27 buys, 5 sales), the last on Dec 4, 2024.
  • -3.8% median (-1.6% mean) 90-day return after 6 previous buys.
  • The trade is 0.1% of the 374,374 shares held after it.
  • 1 other insider bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Radoff Bradley Louis bought about $1.1K of HHS on Dec 5, 2024; 1 other insider bought within 30 days and 5 funds added in the latest 13F quarter.
128 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 123 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
5 funds bought in last quarter
below 89% of Services
Revenue
-13.9% year over year
below 86% of Services
Margin
-0.5% net margin
below 61% of Services
Buybacks
no share repurchases reported
Short interest
0.9% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 68% of Services
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch HHS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+0.3%12M
-49%-26%-4%+19%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns HHS: institutional holders (13F)

13F holdings, latest reported quarter
BLAIR WILLIAM & CO/IL
660,845 sh
$1.4M
WESTERLY CAPITAL MANAGEMENT, LLC
635,000 sh
$1.4M
VANGUARD CAPITAL MANAGEMENT LLC
259,036 sh
$559.5K
RAFFLES ASSOCIATES LP
175,514 sh
$379.1K
Krilogy Financial LLC
152,379 sh
$329.1K

Congress trades in HHS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

HHS planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

HHS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$29.2K position · as of 2026-06-30
0.0%
Omni Small-Cap Value Fund
$16.6K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$6.4K position · as of 2026-06-30
0.0%
JNL/DFA U.S. Small Cap Fund
$2.6K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$477 position · as of 2026-06-30
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$149.4K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Brian Linscott
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$1.0M
-$27.6K
$452.9K
-75%
n/a
2023
$707.0K
$420.1K
$611.2K
-57%
n/a
2022
$2.4M
$1.3M
$421.6K
-43%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 5 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
DASHABNBSEETSYFICOXMTRACNZGFLYWMAMAXPHR

HHS financials

Revenue growth
-13.9%
XBRL, annual
Net margin
-0.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$154.6M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-3.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$1.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.20x
long-term 2022-12-31 (42 months older than the period end) plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
0.43x
TTM operating cash flow over long-term 2022-12-31 (42 months older than the period end) plus current 2026-06-30
Return on equity
-30.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-6.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-8.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$27.0M
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term 2022-12-31 (42 months older than the period end) plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-5.0%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$159.6M$185.2M$191.5M$206.3M
Operating income$386.0K$2.1M$3.4M$15.1M
Net income-$811.0K-$811.0K-$30.3M-$1.6M
EPS (diluted)-0.11-4.15-0.214.75
Operating cash flow-$1.7M-$3.0M$10.5M$28.8M
Cash$5.6M$9.8M$18.4M$10.4M
Long-term debtn/an/an/a$0
Buybacksn/a$0$2.4M$0
SEC XBRL, fiscal years, as known on 2026-10-27

HHS Stock Sonar score 5/7 axes

Find similar shapesCompare

HHS ranks highest on risk and compliance (74th percentile) and financial health (63rd), and lowest on institutional and government (11th), among Services peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
26
Inputs
  • Return on equity-30.4% · 18 pct, sector of 207
  • Return on assets-6.2% · 35 pct, sector of 269
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-8.3% · 25 pct, sector of 203
Financial health
63
Inputs
  • Debt to equity0.20x · 59 pct, sector of 228
  • Cash flow to debt0.43x · 67 pct, sector of 199
Growth
14
Inputs
  • Revenue growth, YoY-13.9% · 14 pct, sector of 341
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
11
Inputs
  • Funds adding, latest quarter5 · 11 pct, sector of 243
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
74
Inputs
  • Short interest, % of float+0.9% · 66 pct, sector of 383
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+5.4% · 82 pct, sector of 227
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies